Quote:

---

I'm not sure the reasons behind both doses being offered...since 700 MG has not shown to make much difference in effectiveness in other clinicals

---

Only in HIV and NASH do we have comparators between 350mg and 700mg. In HIV of course 700mg is superior, in NASH 350mg came out ahead possibly because of a skewed patient population. With the other trials it was all 700mg except the breast cancer compassionate use study with unknown dosages and the cancer basket trial with 525mg. We know why the trials that didn't hit statistical significance did so. Outside of severe/critical Covid it was all small patient populations. Severe/critical Covid we had two doses in a four week trial and in mild/moderate Covid we had a flawed protocol involving a near zero symptomology score in some patients.

Leronlimab's effect on everything is based on it's superior ability to block CCR5 and the downward cascade from that. The greater the receptor occupancy the greater the effect on all the negative consequences associated with inflammation, autoimmunity and immune dysregulation. Using 350mg would cripple leronlimab's response and would have less receptor occupancy than maraviroc. If you want to see failed trials then of course we could use 350mg.